242 related articles for article (PubMed ID: 6737958)
1. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Kamenetskiĭ VK
Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958
[No Abstract] [Full Text] [Related]
2. A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease.
De Michele G; Mengano A; Filla A; Trombetta L; Campanella G
Acta Neurol (Napoli); 1989 Dec; 11(6):408-14. PubMed ID: 2694799
[TBL] [Abstract][Full Text] [Related]
3. [Drug therapy of Parkinson's disease].
Zhou XD
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
[No Abstract] [Full Text] [Related]
4. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
[No Abstract] [Full Text] [Related]
5. Madopar HBS and the decompensated phase of Parkinson disease.
Caraceni T; Nordera N; Lamperti E; Lorizio A
Ital J Neurol Sci; 1989 Aug; 10(4):407-14. PubMed ID: 2793413
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
7. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
[TBL] [Abstract][Full Text] [Related]
9. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Dessibourg CA; Gachoud JP
Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic strategies and tactics in parkinsonism].
Birkmayer W
Wien Med Wochenschr; 1986 Aug; 136(15-16):408-11. PubMed ID: 3097964
[TBL] [Abstract][Full Text] [Related]
11. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Martinez-Campos A; Giovannini P; Novelli A; Cocchi D; Caraceni T; Müller EE
Acta Endocrinol (Copenh); 1982 Mar; 99(3):344-51. PubMed ID: 6803485
[TBL] [Abstract][Full Text] [Related]
12. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
Rabadeau Dumas JL; Rondot P; Cardon P
Therapie; 1977; 32(2):161-72. PubMed ID: 898124
[No Abstract] [Full Text] [Related]
13. [Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
Liu DK
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Apr; 13(4):223-6. PubMed ID: 6790255
[No Abstract] [Full Text] [Related]
14. Parkinsonism in the elderly.
Hildick-Smith M
Curr Med Res Opin; 1982; 7(Suppl 1):14-22. PubMed ID: 7105791
[TBL] [Abstract][Full Text] [Related]
15. [Combined (surgical and drug) therapy of parkinsonism].
Kandel' EI; Iadgarov IS
Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(8):1157-61. PubMed ID: 6388198
[TBL] [Abstract][Full Text] [Related]
16. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
Rondot P
Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
[No Abstract] [Full Text] [Related]
17. Madopar versus sinemet. A clinical study on their effectiveness.
Korten JJ; Keyser A; Joosten EM; Gabreëls FJ
Eur Neurol; 1975; 13(2):65-71. PubMed ID: 1095374
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
19. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Birkmayer W; Birkmayer GD
J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256
[TBL] [Abstract][Full Text] [Related]
20. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
Savery F
Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
[No Abstract] [Full Text] [Related]
[Next] [New Search]
